SG11202101945PA - Peptide therapeutics for the treatment of cancer and uses thereof - Google Patents

Peptide therapeutics for the treatment of cancer and uses thereof

Info

Publication number
SG11202101945PA
SG11202101945PA SG11202101945PA SG11202101945PA SG11202101945PA SG 11202101945P A SG11202101945P A SG 11202101945PA SG 11202101945P A SG11202101945P A SG 11202101945PA SG 11202101945P A SG11202101945P A SG 11202101945PA SG 11202101945P A SG11202101945P A SG 11202101945PA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
peptide therapeutics
therapeutics
peptide
Prior art date
Application number
SG11202101945PA
Inventor
Keith Robinson
Wei Luo
Original Assignee
Microquin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microquin Ltd filed Critical Microquin Ltd
Publication of SG11202101945PA publication Critical patent/SG11202101945PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11202101945PA 2018-08-27 2019-08-27 Peptide therapeutics for the treatment of cancer and uses thereof SG11202101945PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862723428P 2018-08-27 2018-08-27
PCT/US2019/048414 WO2020046997A1 (en) 2018-08-27 2019-08-27 Peptide therapeutics for the treatment of cancer and uses thereof

Publications (1)

Publication Number Publication Date
SG11202101945PA true SG11202101945PA (en) 2021-03-30

Family

ID=69643321

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101945PA SG11202101945PA (en) 2018-08-27 2019-08-27 Peptide therapeutics for the treatment of cancer and uses thereof

Country Status (12)

Country Link
US (1) US20210361742A1 (en)
EP (1) EP3844262A4 (en)
JP (1) JP2021534826A (en)
KR (1) KR20210097690A (en)
CN (1) CN113195704A (en)
AU (1) AU2019327424A1 (en)
BR (1) BR112021003812A2 (en)
CA (1) CA3111216A1 (en)
IL (1) IL281091A (en)
MX (1) MX2021002245A (en)
SG (1) SG11202101945PA (en)
WO (1) WO2020046997A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720192A2 (en) * 2006-10-24 2013-12-31 Basf Plant Science Gmbh METHOD FOR GENERATING OR INCREASING AT LEAST A BIOTROPHIC FUNGUS ON A PLANT OR PART OF A PLANT, ARTIFICIAL NUCLEIC ACID SEQUENCE, RECOMMINANT RECOMMINANT EXPRESSION CASSETTE, RECOMMINANT RECOMMINANT EXPRESSION CASSETTE

Also Published As

Publication number Publication date
EP3844262A4 (en) 2022-09-14
AU2019327424A1 (en) 2021-04-15
US20210361742A1 (en) 2021-11-25
WO2020046997A1 (en) 2020-03-05
EP3844262A1 (en) 2021-07-07
MX2021002245A (en) 2021-08-11
JP2021534826A (en) 2021-12-16
IL281091A (en) 2021-04-29
BR112021003812A2 (en) 2021-07-27
KR20210097690A (en) 2021-08-09
CA3111216A1 (en) 2020-03-05
CN113195704A (en) 2021-07-30

Similar Documents

Publication Publication Date Title
IL279347A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
FI3773689T3 (en) Antigenic peptides for prevention and treatment of cancer
ZA201905851B (en) Peptides and methods for the treatment of diabetes
EP3428178A4 (en) Peptide for preventing or treating inflammatory diseases and use thereof
EP3820492A4 (en) Apmv and uses thereof for the treatment of cancer
ZA202100587B (en) Peptide compounds and therapeutic uses of same
IL275525A (en) Pharmaceutical composition for the treatment of cancer
IL272147A (en) Methods and compositions for the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
GB202005189D0 (en) Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
GB201812647D0 (en) Viral vectors and methods for the prevention or treatment of cancer
EP3428179A4 (en) Peptide for preventing or treating inflammatory diseases and use thereof
IL280262A (en) Compositions and methods for the treatment of cancer
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
GB201810635D0 (en) Peptides and cancer treatment
IL281091A (en) Peptide therapeutics for the treatment of cancer and uses thereof
EP3648789C0 (en) Mtmr2-s polypeptide for use in the treatment of myopathies
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
AU2018902173A0 (en) Antibody-Drug-Conjugates And Uses Thereof For The Treatment Of Cancer
HK1251590A1 (en) Phenylalanine-free protein for the treatment of pku
IL282157A (en) Compounds and therapeutic uses thereof
IL277734A (en) Application of pedf-derived short peptides in the treatment of osteoarthritis
IL281782A (en) Pharmaceutical combination for the treatment of cancer